Syndeio Biosciences
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Syndeio Biosciences sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Syndeio Biosciences: 7 sponsored US clinical trials, 2 recruiting.
Syndeio Biosciences sponsors 7 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Major Depressive Disorder, with 3 trials.
Upper-quartile sponsor footprint
Syndeio Biosciences sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
NCT07115329
Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
NCT06547489
Pharmacokinetics of Zelquistinel in Fasted or Fed State
NCT07099989
Multiple Ascending Dose and Electroencephalography Trial of GATE-202 in Healthy Volunteers
NCT05597241
Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers
NCT04618263
Zelquistinel in the Treatment of Adults With Major Depressive Disorder
NCT03726658
AGN-241751 in the Treatment of Major Depressive Disorder
NCT03586427
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 3 |
Therapeutic Areas
What is open in the Syndeio Biosciences pipeline
2 recruiting of 7 indexed (29% open); 3 completed (43%).
Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).
Top condition: Major Depressive Disorder (3 trials), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Syndeio Biosciences: open-pipeline peers nationwide
Peers matched on 7 registered trials and 29% open enrollment, not the therapeutic-area sidebar.
Syndeio Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 29% open enrollment (± trial volume)
- Alabama Physical Therapy & Acupuncture · 29% recruiting · 14 trials
- AlloSource · 29% recruiting · 7 trials
- Alnylam Pharmaceuticals · 29% recruiting · 49 trials
- Annovis Bio · 29% recruiting · 7 trials
Related
What to do with this Syndeio Biosciences page
7 registered trials is a research-attention snapshot, not an endorsement of Syndeio Biosciences or any single study.
- 2 of Syndeio Biosciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Major Depressive Disorder is the condition Syndeio Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Major Depressive Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Syndeio Biosciences pipeline card: 7 registered trials from official public datasets.Report a data error.